Bortezomib is a first-in-class proteasome inhibitor that blocks the 26S proteasome, inducing apoptosis in malignant plasma cells, used as a cornerstone therapy for multiple myeloma and mantle cell lymphoma. Simson Pharma's Bortezomib reference standard and impurities support the demanding stability-indicating testing this oncology injectable requires.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Bortezomib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.